The study uses real-world data from US health insurance companies covering a total of 97,690 patients to investigate how semaglutide and tirzepatide influence the risk of hospitalisation due to heart failure or death in patients with HFpEF and concomitant cardiometabolic comorbidities. In the analyses, 58,333 patients started on semaglutide, 11,257 on tirzepatide and 28,100 patients received sitagliptin as a comparator. Patients taking semaglutide or tirzepatide showed a significant reduction of over 40% in the combined endpoint of heart failure hospitalisation or death compared to sitagliptin, although a direct comparison of the two drugs did not show a significant advantage of tirzepatide over semaglutide.
Link to the publication: Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (Krüger et al., JAMA, 2025)
Link to the news: New obesity drugs can reduce heart failure risks by over 40 per cent
